The BCI category that motor and speech restoration overshadowed: Nia Therapeutics has FDA Breakthrough Designation for a preclinical brain implant for TBI-related memory loss

By Inside BCI · July 5, 2026

Someone who survived a moderate-to-severe traumatic brain injury five years ago and now finds that certain memories from before the injury are missing, and that new memories are harder to form and easier to lose, is at the specific clinical target of a device that has just cleared its first US regulatory milestone. Nia Therapeutics, a small Boston-area company that most BCI coverage does not track, announced on 13 March 2026 that the US Food and Drug Administration had granted its Smart Neurostimulation System (SNS) a Breakthrough Device Designation for the treatment of episodic memory loss in adults with prior moderate-to-severe traumatic brain injury and persistent memory deficits. The company describes the SNS as the first device to receive Breakthrough Designation specifically for TBI-related memory loss; that specific-first claim is a company assertion because the FDA does not publicly disclose Breakthrough Designations unless the sponsor discloses them first, so the claim is not independently falsifiable from public data but is defensible in its narrow framing. Nia estimates, citing a 2015 US Centers for Disease Control and Prevention Report to Congress, that more than 4.3 million Americans live with TBI-related disability.

Inside BCI has not previously covered Nia Therapeutics or the memory-implant BCI category more broadly. That coverage gap is worth naming: the visible BCI narrative from the past two years has centred on motor and speech restoration in cervical spinal cord injury and ALS through Neuralink, Synchron, Paradromics, Precision Neuroscience, Neuracle, and BrainGate. Memory and cognition sit alongside vision (Cortigent Orion), pain (Nevro), tremor (Cala Health), and psychiatric-state indications (Motif Neurotech’s treatment-resistant depression work) as commercial verticals adjacent to the dominant motor-restoration lane. Nia is the company most directly built to fill the memory slot. The company sits inside a scientific lineage that traces to the US Defense Advanced Research Projects Agency’s Restoring Active Memory (RAM) programme, which began funding memory-decoding neuroprosthesis research at the University of Pennsylvania in 2014 under principal investigator Michael Kahana at Penn’s Computational Memory Lab. Nia was founded in 2018 in Allston, Massachusetts, licensed Kahana lab algorithms from Penn, and now has 60-channel cortical hardware and an FDA Breakthrough Designation without yet having implanted the device in a human.

Who runs Nia

Nia’s chief executive is Michael J. Kahana, PhD, the Edmund and Louise Kahn Term Professor of Psychology at the University of Pennsylvania and co-founder of Penn’s Computational Memory Lab. Kahana led the Penn team that participated in DARPA’s RAM programme from its 2014 start and is co-inventor of the SNS core technology. He is Nia’s co-founder and CEO. Nia’s co-founder, president, and chief technology officer is Daniel S. Rizzuto, PhD, whose academic path runs from a Brandeis neuroscience doctorate through a Caltech neural engineering postdoc to a Director of Cognitive Neuromodulation role at Penn. Rizzuto’s prior industry experience spans Northstar Neuroscience, Varian Medical Systems, the Swedish Neuroscience Institute, and the Allen Institute for Brain Science. Nia’s medical advisors include Ramon Diaz-Arrastia, Presidential Professor of Neurology at Penn and Director of the TBI Clinical Research Center; Bob Gross, Chair of Neurosurgery at Rutgers; Brad Lega at UT Southwestern; and Geoff Aguirre at Penn. Nia’s independent board directors include Milton Morris (former CEO of Neuspera Medical), Bob Greenberg (chief executive of huMannity and former Second Sight founder), Tim Marjenin (Vice President of Regulatory Affairs at MCRA and a former FDA Branch Chief for Neurological Devices), and Sat Pannu (Vice President at Nevro).

Nia’s corporate identity is small compared with its scientific pedigree. The team page names roughly a dozen full-time technical staff. The company has not disclosed venture funding rounds, lead investors, or a specific runway on its public materials. That reticence is typical for a US medical-device company in the year before its first-in-human study.

Per Nia’s own product materials and the Brain Stimulation validation paper published in December 2025, the Smart Neurostimulation System is a fully implantable wireless neurostimulation platform comprising a neural implant, an external processor worn behind the ear, four depth leads, and a cloud-based analytics platform. Nia’s press releases describe the device as recording from 60 channels across four brain regions, with the recorded neural activity used to trigger closed-loop stimulation of the lateral temporal cortex. The specific four brain regions used for recording are not named in Nia’s public press materials; the stimulation target that is named is the lateral temporal cortex. The Rizzuto Brain Stimulation paper describes the integrated pulse generator as sensing local field activity from 60 electrodes with four reference electrodes. Nia’s technology page separately describes the hardware as four depth leads with 16 electrodes each for a total of 64 electrodes, which is a discrepancy with the paper’s description of 8-channel depth leads. Nia has not publicly reconciled the two descriptions in materials Inside BCI could access; the 60-recording-channels figure is what appears in both press-release and peer-reviewed sources.

Nia’s press releases describe the SNS 60-channel architecture as an order-of-magnitude increase over commercially available devices. That framing invites a specific comparison against the two most-referenced commercial closed-loop cortical and subcortical stimulation devices in the field. That comparison needs to be done with care because the three devices use different denominations for what they count.

The NeuroPace RNS System, approved by the FDA in 2013 for responsive stimulation in refractory focal epilepsy, uses two leads implanted per patient, each with four electrode contacts, for eight total electrode contacts. The RNS Neurostimulator provides four bipolar sensing channels of continuous electrocorticography sampled at 250 Hz, per NeuroPace’s physician manual. Nia’s press-release comparison, which states that the RNS records from up to six channels, is not consistent with NeuroPace’s own published technical documentation, which lists four amplifier channels. Inside BCI is using the NeuroPace-published figure of four sensing channels rather than Nia’s press-release figure of six.

The Medtronic Percept, approved by the FDA in 2020 for deep brain stimulation with concurrent local-field-potential sensing (BrainSense), uses two leads for bilateral DBS with four or eight electrode contacts per lead depending on the lead model (Medtronic 3387 or 3389 legacy leads carry four ring contacts; the newer SenSight directional lead carries eight segments). Percept’s BrainSense functionality records two bipolar local-field-potential channels, one per hemisphere. Percept’s stimulation supports 16 independent current sources across the electrode contacts. Nia’s press-release framing that Percept records from up to four is best read as referring to electrode contacts per lead rather than sensing channels; the sensing-channel count is two.

Compared on the like-for-like sensing-channel denomination, then, Nia’s SNS is designed for 60 recording channels versus NeuroPace RNS at four bipolar sensing channels and Medtronic Percept at two BrainSense sensing channels. That is a 15-times ratio against the RNS and a 30-times ratio against the Percept. Compared on electrode-contact hardware count, Nia’s SNS is 32 to 64 electrodes across four leads versus the RNS at eight electrodes and the Percept at eight to sixteen electrodes. The “order-of-magnitude” framing holds on the sensing-channel comparison. The commercial context matters: RNS and Percept are FDA-approved for specific clinical indications (focal epilepsy and Parkinson’s / essential tremor respectively) where their recording channel counts reflect what focal seizure detection and LFP-guided DBS require. Their low channel counts are engineering choices for their approved indications, not technological ceilings.

The scientific evidence, split across two studies

Nia’s memory-restoration case is not built on a single paper. It rests on two studies published in the same journal at different times, doing different things.

The first is Kahana et al., “Biomarker-guided neuromodulation aids memory in traumatic brain injury,” published in Brain Stimulation volume 16 in 2023 (digital object identifier 10.1016/j.brs.2023.07.002). This study used an externalised research prototype in neurosurgical patients who were being monitored for epilepsy and who had a history of moderate-to-severe TBI. The reported result was a 19 per cent improvement in verbal recall with biomarker-guided stimulation compared to sham stimulation. This is the human evidence base for the memory indication.

The second is Rizzuto et al., “A wireless, 60-channel, AI-enabled neurostimulation platform,” published in Brain Stimulation volume 19 issue 1 with online publication on 20 December 2025 and print issue in January 2026 (digital object identifier 10.1016/j.brs.2025.103013). This study validated the SNS platform hardware in three freely-moving sheep. The paper reports movement classifiers trained on the streamed local-field-potential data, with cross-validated area-under-the-curve exceeding 0.95. The paper’s decoded outputs are behavioural-state (movement) classifiers, not memory decoders. Its clinical framing is that the platform is now sufficient for chronic wireless recording and stimulation across a broad cortical footprint, positioning it for memory-decoder work in a subsequent study. Funding for the sheep study is disclosed via Crossref metadata as U.S. Army Medical Research and Development Command, the U.S. Department of Defense, and the National Metal and Materials Technology Center under award 20-06-MOM, not directly DARPA. On the Rizzuto paper specifically, senior author Kahana lists Nia Therapeutics as affiliation, not Penn; the Penn affiliation on that paper is held by Sandhitsu R. Das.

The two studies together are the evidence base for the FDA Breakthrough Designation: the 2023 Kahana paper demonstrates that biomarker-guided stimulation improves recall in humans with TBI history using an externalised prototype, and the 2025 Rizzuto paper demonstrates that Nia’s fully implantable wireless platform can chronically record and stimulate at 60 channels in a large-animal model. The bridging step, which is memory decoding and closed-loop stimulation with the SNS device in humans, has not yet been demonstrated. That is the point of the first-in-human study Nia says it is preparing to enable through an Investigational Device Exemption application it plans to file in 2026.

Why memory / cognition is an underbuilt BCI vertical

The visible BCI narrative to date has been about restoration in paralysis. Neuralink’s CAN-PRIME first-Canadian ALS patient, which Inside BCI covered on 4 July 2026, is a canonical example: an ALS-affected patient using a Neuralink implant to control a phone and computer by thought. Synchron, Paradromics, Precision Neuroscience, Neuracle, and the BrainGate consortium all operate in that same paralysis-restoration lane, targeting cervical spinal cord injury, ALS, and brainstem stroke.

Nia sits in a distinct lane. Its clinical target is not paralysis but acquired cognitive deficit: memory loss in patients who survived a TBI, retain motor function, and often retain independent living, but experience persistent episodic memory impairment that shapes daily function and quality of life. That patient population is larger by orders of magnitude than the cervical spinal cord injury and ALS populations that anchor the motor-restoration lane. The commercial category that Nia is building toward is closer to Alzheimer’s therapeutic development in scale (Eli Lilly’s Kisunla and Eisai’s Leqembi are the pharmacological adjacencies; Cognito Therapeutics’ non-invasive gamma-frequency light and sound stimulation is a device adjacency) than to Neuralink’s cervical SCI cohort.

Two adjacent BCI players are worth flagging. Motif Neurotech, which Inside BCI covered in prior reporting, targets treatment-resistant depression via cortical stimulation. That is a psychiatric-state indication rather than a memory indication, and the two should not be conflated, but both sit in the cognitive and psychiatric-state modulation lane rather than motor restoration. NeuroPace’s RNS System, approved for focal epilepsy, has had off-label and academic exploration in cognitive-adjacent indications. Nia is the most focused commercial entrant on memory specifically.

Nia’s device positioning also connects to a broader observation about the DARPA science base for the US BCI category. DARPA’s RAM programme (2014 onwards, now marked complete on the DARPA programme page) was one of a set of Biological Technologies Office programmes that funded academic BCI research at levels US venture capital could not match at the time, and the current commercial cohort in the US is largely built on the technical and personnel base those programmes seeded. RAM produced Nia. Other DARPA neuroscience programmes have produced or influenced other commercial descendants, some direct and some indirect. Naming Nia as “the RAM commercial descendant” would overstate the exclusivity because DARPA does not publicly list all RAM performers in a form that would let Inside BCI verify the counterfactual, but the RAM-to-Nia pipeline through Kahana’s Penn lab is well-documented.

What to watch

The first signal is Nia’s Investigational Device Exemption application to the FDA. Nia has stated publicly that the application is planned for 2026. IDE approval is the gate to the first-in-human early feasibility study. Timing of the IDE submission, and the FDA response window, will convert Nia’s story from preclinical-with-Breakthrough into first-in-human.

The second signal is the first-in-human study design when disclosed. The Kahana 2023 paper was in neurosurgical epilepsy patients with a history of TBI, which is a specific and small population. Whether Nia’s first-in-human study enrolls the same epilepsy-with-TBI population, a broader TBI-only cohort, or a different anatomical target is a meaningful commercial signal about how Nia intends to derisk the pivotal trial and eventual PMA or De Novo application.

The third signal is the venture-funding disclosure. Nia has not publicly disclosed its funding history. A named Series A or B round with disclosed investors will be a signal about how the private capital market is pricing the memory-implant category relative to the motor-restoration lane.

The fourth signal is whether adjacent memory-restoration and cognition-restoration companies emerge to build a competitive category rather than leaving Nia as the sole named entrant. Cognito Therapeutics’ non-invasive gamma-frequency stimulation for Alzheimer’s is one adjacency. Academic groups from BrainGate and Cortec have explored memory-related applications of implantable cortical BCIs without spinning out commercial vehicles. Whether the commercial category consolidates around Nia or diversifies with new entrants is a signal for the broader BCI investment thesis.

Sources

market Nia-Therapeutics SNS Smart-Neurostimulation-System FDA-Breakthrough-Device-Designation TBI episodic-memory Michael-Kahana Daniel-Rizzuto DARPA Restoring-Active-Memory University-of-Pennsylvania Allston-Massachusetts closed-loop-neurostimulation

Who runs Nia

What the SNS actually is

The scientific evidence, split across two studies

Why memory / cognition is an underbuilt BCI vertical

What to watch

Weekly BCI Brief in your inbox